Jin Rong Jie·2025-08-26 18:00Group 1 - The stock price of CanSino on August 26 was 84.82 yuan, down 3.37 yuan or 3.82% from the previous trading day [1] - The opening price was 87.70 yuan, with a high of 87.99 yuan and a low of 84.60 yuan, and the trading volume was 33,388 hands with a transaction amount of 287 million yuan [1] Group 2 - CanSino is a biopharmaceutical company focused on vaccine research, production, and commercialization, with main products including meningococcal vaccines and COVID-19 vaccines [1] - The company belongs to the bioproducts sector [1] Group 3 - According to the latest semi-annual report, CanSino achieved operating revenue of 382 million yuan in the first half of 2025, a year-on-year increase of 26% [1] - The net profit attributable to the parent company was a loss of 13.49 million yuan, significantly narrowing the loss by 94.02% compared to a loss of 225 million yuan in the same period last year [1] - During the reporting period, sales revenue from two types of combined meningococcal vaccines reached approximately 364 million yuan, a year-on-year increase of 38.43% [1] Group 4 - On August 26, the net outflow of main funds for CanSino was 71.34 million yuan, accounting for 0.73% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow was 67.14 million yuan, representing 0.69% of the circulating market value [1]